Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data.

Objectives: To compare the second-line treatments on survival after trastuzumab failure in HER2-positive metastatic gastric cancer. Methods: We retrospectively included 57 patients. Of whom, 32 (56%) received paclitaxel, whereas 25 (44%) received 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI). We analyzed the patient characteristics, and survival outcomes of the second-line treatment. Results: The median PFS was 3.5 months in the paclitaxel-group and 4.8 months in the FOLFIRI-group (p=0.569). The median overall survival (OS) was 6.0 months in paclitaxel-group and 11.0 months in FOLFIRI-group (p=0.410). FOLFIRI provided a significant OS advantage over paclitaxel in patients with grade 3 tumors or who did not have an objective first-line treatment response. Conclusion: FOLFIRI may be recommended as a preferred option over paclitaxel in patients with these identified risk factors. [ABSTRACT FROM AUTHOR]